Allopregnanolone effects on short term memory

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-005565-10-SE

Enrollment

Registered

2005-12-20

Start date

2006-01-31

Completion date

Unknown

Last updated

2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy women 35-40 years of age

Interventions

Product Code: Allopregnanolone Pharmaceutical Form: Injection* INN or Proposed INN: 5alfa-hydroxy 5 alfa-pregnan 20-one CAS Number: 516-54-1 Current Sponsor code: Allopregnanolone Concentration unit:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 35-40. Physically healthy according to medical history, examination and routine blood chemistry. Informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Chronic disorder requiring daily medication. Ongoing depressive- and/or anxiety disorder Smoking > 5 cigarettes/day Known or suspected disorder affecting memory Ongoing treatment with any hormonal compound Ongoing treatment with any CNS-active compound

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate allopregnanolone effect on short term memory.;Secondary Objective: ;Primary end point(s): Test battery for episodic memory Test battery for semantic memory Test battery for executive functions (N-back)	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026